Ashland announces executive organization changes to personal care and specialty additives
WILMINGTON, Del. , April 03, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH), the global additives and specialty ingredients company today announced executive organization changes to its personal care and specialty additives businesses.
Jim Minicucci, senior vice president strategy, mergers and acquisitions, and portfolio management, Ashland, becomes senior vice president and general manager, personal care, Ashland.
Effective April 15, 2024, Dago Caceres, will become vice president and general manager, specialty additives, Ashland. Caceres has held previous leadership roles with IFF, DuPont, Dow, Rohm and Haas and FMC.
“Since joining Ashland last May, Jim has worked across the company with our businesses and technology leaders to hone our strategy, and his international experience and strong track record for delivering top and bottom-line results will bring great value as we invest to expand our personal care business globally,” said Guillermo Novo, chair and chief executive officer, Ashland. “Dago is a results-oriented business leader with extensive experience in strategy, marketing, sales, business development and project management. He has a proven track record in leading multi-functional, cross-regional teams to achieve business results,” continued Novo. “Jim, Dago and their teams will enable us to increase the speed and impact of our products and new technology platforms in high performance, new applications and markets,” concluded Novo.
Both Minicucci and Caceres will report to Novo. The company will announce the new leader for strategy, mergers and acquisitions, and portfolio management soon.
About Ashland
Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environment, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 3,800 passionate, tenacious solvers thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more.
™ Trademark, Ashland or its subsidiaries, registered in various countries.
FOR FURTHER INFORMATION:
Investor Relations: | Media Relations: |
William Whitaker | Carolmarie C. Brown |
+1 (614) 790-2095 | +1 (302) 995-3158 |
wcwhitaker@ashland.com | ccbrown@ashland.com |
Attachment
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?